Profund Advisors LLC Has $1.66 Million Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Profund Advisors LLC raised its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 10.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 156,724 shares of the company’s stock after buying an additional 14,377 shares during the quarter. Profund Advisors LLC’s holdings in Roivant Sciences were worth $1,657,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the company. Rubric Capital Management LP raised its stake in shares of Roivant Sciences by 15.0% in the second quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock valued at $243,110,000 after purchasing an additional 3,000,000 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Roivant Sciences by 14.6% in the first quarter. Vanguard Group Inc. now owns 8,106,332 shares of the company’s stock valued at $85,441,000 after purchasing an additional 1,030,681 shares in the last quarter. Norges Bank acquired a new position in shares of Roivant Sciences in the fourth quarter valued at $41,506,000. First Trust Advisors LP raised its stake in shares of Roivant Sciences by 434.8% in the fourth quarter. First Trust Advisors LP now owns 2,739,438 shares of the company’s stock valued at $30,764,000 after purchasing an additional 2,227,192 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Roivant Sciences by 2.2% in the second quarter. Bank of New York Mellon Corp now owns 2,686,538 shares of the company’s stock valued at $28,397,000 after purchasing an additional 58,541 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently commented on ROIV. Piper Sandler upped their target price on Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Bank of America increased their price objective on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research note on Wednesday, September 11th. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research note on Thursday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.39.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $11.97 on Monday. The stock’s fifty day moving average is $11.46 and its 200-day moving average is $11.05. The company has a debt-to-equity ratio of 0.05, a quick ratio of 27.91 and a current ratio of 27.91. The stock has a market capitalization of $8.84 billion, a PE ratio of 2.37 and a beta of 1.25. Roivant Sciences Ltd. has a 52 week low of $8.24 and a 52 week high of $13.24.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Thursday, August 8th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.33. The company had revenue of $55.10 million for the quarter, compared to analysts’ expectations of $30.72 million. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The business’s revenue for the quarter was up 155.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.38) earnings per share. Equities research analysts expect that Roivant Sciences Ltd. will post -1.14 EPS for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.